Comparison of the association of risperidone and quetiapine with deteriorating performance in walking and dressing in subjects with Parkinson's disease: a retrospective cohort study using administrative claims data.

abstract：:Because of the limitations in efficacy and safety of the older tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI) a number of new approaches have been made in recent years to the treatment of depression to obtain more effective, more rapidly acting, better tolerated and safer drugs. One tactic has...

journal_title：International clinical psychopharmacology

authors： Silverstone T

更新日期：1992-06-01 00:00:00

abstract：:The interaction between a single dose of 20 mg of prazepam and 0.5 g/kg body weight ethanol was investigated in 12 healthy male volunteers by nine objective performance tests, eight visual analogue self-rating scales and measurement of prazepam and ethanol plasma concentrations, using a double-blind three-way crossove...

journal_title：International clinical psychopharmacology

authors： Girre C,Hirschhorn M,Bertaux L,Palombo S,Fournier PE

更新日期：1991-01-01 00:00:00

abstract：:A variety of cognitive impairments can be observed in patients with schizophrenia, including substantial reductions in the intelligence quotient (IQ). I propose that these impairments can be best understood in terms of the abnormal processes underlying the signs and symptoms manifested by the patient at the time of th...

journal_title：International clinical psychopharmacology

authors： Frith CD

更新日期：1995-09-01 00:00:00

abstract：:Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice. This was a multicentre, double-blind, randomized trial carried out in France. The duration of treatment was 8 weeks. Patie...

journal_title：International clinical psychopharmacology

authors： Patris M,Bouchard JM,Bougerol T,Charbonnier JF,Chevalier JF,Clerc G,Cyran C,Van Amerongen P,Lemming O,Høpfner Petersen HE

更新日期：1996-06-01 00:00:00

abstract：:Benzodiazepines are commonly used for behavioral and psychiatric symptoms of dementia, despite their numerous adverse effects and the lack of evidence regarding their efficacy in this context. We studied longitudinal benzodiazepines exposure in incident cases of Alzheimer's disease and related syndromes (ADRS) in Fran...

journal_title：International clinical psychopharmacology

authors： Poncet M,Gardette V,Couret A,Renoux A,Lapeyre-Mestre M,Gallini A

更新日期：2020-09-01 00:00:00

abstract：:The effect of prophylactic treatment with depot antipsychotic drugs was examined in 16 patients with bipolar affective disorder. The frequency and duration of illness episodes occurring during depot treatment was compared to that which occurred when these patients were treated with other agents over a corresponding ti...

journal_title：International clinical psychopharmacology

authors： White E,Cheung P,Silverstone T

更新日期：1993-07-01 00:00:00

abstract：:Since the introduction in 1993 of the novel serotonin-dopamine antagonist antipsychotic risperidone, over 12 million patient-months of exposure to the drug have been accumulated. Further studies have confirmed the efficacy of risperidone across a broad range of patients with schizophrenia who were not represented in t...

journal_title：International clinical psychopharmacology

authors： Gutierrez-Esteinou R,Grebb JA

更新日期：1997-09-01 00:00:00

abstract：:Duloxetine, an inhibitor of serotonin and norepinephrine reuptake, has been approved for the treatment of major depressive disorder. In this analysis, data from eight, double-blind, placebo-controlled duloxetine trials were pooled, and the response to duloxetine treatment (40-120 mg/day) was compared between patients ...

journal_title：International clinical psychopharmacology

authors： Perahia DG,Kajdasz DK,Royer MG,Walker DJ,Raskin J

更新日期：2006-09-01 00:00:00

abstract：:Medication is critical in schizophrenia therapy, and prescription patterns have changed considerably over the past 20 years in China. This study attempts to evaluate the prescription patterns of antipsychotics for inpatients with schizophrenia in China and to identify factors influencing these patterns. Claims data of...

journal_title：International clinical psychopharmacology

authors： Xue Q,Xiong X,Feng Y,Yao L,Chen S,Xiang L

更新日期：2014-09-01 00:00:00

abstract：:Twelve normal weight healthy male volunteers participated in a double-blind, placebo-controlled trial of the effects of d- and l-fenfluramine, d-amphetamine, and the interactions between the two isomers of fenfluramine with amphetamine, on cortisol secretion. d-Fenfluramine and d-amphetamine in combination produced th...

journal_title：International clinical psychopharmacology

authors： Feeney S,Goodall E,Silverstone T

更新日期：1993-10-01 00:00:00

abstract：:The therapeutic concentrations of antipsychotic drugs in the patient's plasma water or spinal fluid are identical to their blocking potencies in vitro at the dopamine D2 receptor, with the exception of clozapine which acts at D4. The variation in K values between laboratories stems from the fact that the apparent K va...

journal_title：International clinical psychopharmacology

authors： Seeman P

更新日期：1995-09-01 00:00:00

abstract：:Social phobia and avoidant personality disorder were new diagnoses in the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and were considerably changed in the revised third version (DSM-III-R). A high rate of comorbidity between these disorders was observed, which can be explained ...

journal_title：International clinical psychopharmacology

authors： Dahl AA

更新日期：1996-06-01 00:00:00

abstract：:Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive-compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory. This paper reports a meta-analysis of existing double-blind randomized pl...

journal_title：International clinical psychopharmacology

authors： Fineberg NA,Stein DJ,Premkumar P,Carey P,Sivakumaran T,Vythilingum B,Seedat S,Westenberg H,Denys D

更新日期：2006-11-01 00:00:00

abstract：:Thirty healthy subjects 12 males and 18 females were given the acetylcholinesterase inhibitor pyridostigmine (120 mg) orally. The growth hormone (GH) response was measured as the maximum GH level post-pyridostigmine relative to baseline. Twenty-six subjects increased their GH level in response to pyridostigmine. Respo...

journal_title：International clinical psychopharmacology

authors： Lucey JV,O'Keane V,O'Flynn K,Clare AW,Dinan TG

更新日期：1991-07-01 00:00:00

abstract：:The utility of milnacipran in the treatment of major depression has been the subject of an extensive clinical development programme. Comparative studies with tricyclic antidepressant drugs have demonstrated equivalent efficacy, with improved tolerability, in particular with respect to autonomic effects. In comparison ...

journal_title：International clinical psychopharmacology

authors： Bisserbe JC

更新日期：2002-06-01 00:00:00

abstract：:Paroxetine has been characterized as a highly potent and selective 5-hydroxytryptamine (serotonin) reuptake inhibitor. This selectivity has been demonstrated not only for monoamine uptake mechanisms but also for neurotransmitter receptor systems. The pharmacokinetic studies indicate that paroxetine may be administered...

journal_title：International clinical psychopharmacology

authors： Johnson AM

更新日期：1992-06-01 00:00:00

abstract：:Quetiapine ('Seroquel') is a well-tolerated, novel, atypical antipsychotic with consistent efficacy in the treatment of schizophrenia. To date, no clinical studies have evaluated the effect of quetiapine in patients who only partially respond to conventional antipsychotics, yet this type of patient is most frequently ...

journal_title：International clinical psychopharmacology

authors： Emsley RA,Raniwalla J,Bailey PJ,Jones AM

更新日期：2000-05-01 00:00:00

abstract：:The treatment of negative symptoms of schizophrenia presents a major clinical challenge. This review examines the evidence pertaining to the efficacy, tolerability and safety of adding selective serotonin reuptake inhibitors (SSRIs) to antipsychotic agents in the treatment of negative symptoms in schizophrenia. Import...

journal_title：International clinical psychopharmacology

authors： Silver H

更新日期：2003-11-01 00:00:00

abstract：:C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...

journal_title：International clinical psychopharmacology

authors： Kim SH,Reaven G,Lindley S

更新日期：2011-01-01 00:00:00

abstract：:Three placebo-controlled double-blind and crossover trials were carried out to analyze the effects of oral yohimbine (YOH) 0.8 mg/kg on mood and performance in 16 healthy students. Subjective assessments (visual analogue scales, side-effects on questionnaire) and objective measurements (digit symbols, flicker fusion, ...

journal_title：International clinical psychopharmacology

authors： Mattila M,Seppala T,Mattila MJ

更新日期：1988-07-01 00:00:00

abstract：:The present study aimed to systematically compare overall loss to follow-up, discontinuation rates because of adverse events and discontinuation rates because of a lack of efficacy in published studies assessing the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) compared to other second-g...

journal_title：International clinical psychopharmacology

authors： Gartlehner G,Hansen RA,Carey TS,Lohr KN,Gaynes BN,Randolph LC

更新日期：2005-03-01 00:00:00

abstract：:The prevalence of somnambulistic-like behaviour related to treatment with lithium alone or in combination with other psychotropic medications was evaluated in patients attending a lithium clinic. A written questionnaire on somnambulistic-like behaviour was completed by 389 patients. Information was provided on the tim...

journal_title：International clinical psychopharmacology

authors： Landry P,Warnes H,Nielsen T,Montplaisir J

更新日期：1999-05-01 00:00:00

abstract：:The DIABCARE Q-Net project developed a complete and integrated information technology system to monitor diabetes care, according to the gold standards of the St Vincent Declaration Action Program. This is the first Telematic platform for standardized documentation on medical quality and evaluation across Europe, which...

journal_title：International clinical psychopharmacology

authors： Piwernetz K

更新日期：2001-04-01 00:00:00

abstract：:The effects of moclobemide, 450 mg/day, on sleep were investigated in 12 patients with major depression. The study was carried out over six weeks, divided into three periods: (1) treatment for one week with placebo and measurement to obtain baseline values; (2) treatment with moclobemide for four weeks; and (3) one we...

journal_title：International clinical psychopharmacology

authors： Minot R,Luthringer R,Macher JP

更新日期：1993-01-01 00:00:00

abstract：:Treatment-resistant depression is an important clinical problem presenting a major challenge to clinical psychiatry. While several strategies have been attempted, including medication switch, antidepressant polypharmacy and various augmentative regimens, success remains limited. Amantadine (AMN), an agent traditionall...

journal_title：International clinical psychopharmacology

authors： Stryjer R,Strous RD,Shaked G,Bar F,Feldman B,Kotler M,Polak L,Rosenzcwaig S,Weizman A

更新日期：2003-03-01 00:00:00

abstract：:The sedative properties of two doses (50 and 150 mg) of a benzodiazepine partial agonist, PK 8165 (pipequaline), were compared to diazepam 10 mg and placebo in 12 normal volunteers. The assessment, performed before drug intake and 2 and 5 hours after drug intake, included a battery of visual analogue scales and standa...

journal_title：International clinical psychopharmacology

authors： von Frenckell R,Ansseau M,Bonnet D

更新日期：1986-01-01 00:00:00

abstract：:Post-traumatic stress disorder (PTSD) is frequently treated with antidepressant medications, especially the newer selective serotonergic antidepressants which have documented efficacy in PTSD. Analogous to depression, however, some PTSD patients may not have a satisfactory response to these agents. This case report de...

journal_title：International clinical psychopharmacology

authors： Hamner MB,Frueh BC

更新日期：1998-09-01 00:00:00

abstract：:The introduction of second generation antipsychotics (SGA) represents a major advance in the treatment of schizophrenia. Concerns about the metabolic and cardiovascular adverse effects of the SGA have been widely disseminated. The benefits and risks of these drugs have been studied with a focus on particular organ sys...

journal_title：International clinical psychopharmacology

authors： Barak Y,Swartz M,Plopsky I

更新日期：2005-11-01 00:00:00

abstract：:Zopiclone, a cyclopyrrolone with hypnotic properties was compared with temazepam and placebo in the treatment of insomnia. After a week's washout period, suitable subjects were allocated at random to zopiclone 7.5 mg or temazepam 20 mg or placebo for 2 weeks. Measurements of psychomotor function using the Leed's psych...

journal_title：International clinical psychopharmacology

authors： Ngen CC,Hassan R

更新日期：1990-07-01 00:00:00

abstract：:The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia. In this double-blind, placebo-controlled study the dose of each drug was incre...

journal_title：International clinical psychopharmacology

authors： Hayashi T,Yokota N,Takahashi T,Tawara Y,Nishikawa T,Yano T,Furutani M,Fujikawa T,Horiguchi J,Yamawaki S

更新日期：1997-07-01 00:00:00